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  The disposition kinetics of levofloxacin was investigated 
in six male crossbred calves following single intravenous 
administration, at a dose of 4 mg/kg body weight, into the 
jugular  vein  subsequent  to  a  single  intramuscular  in-
jection of paracetamol (50 mg/kg). At 1 min after the in-
jection of levofloxacin, the concentration of levofloxacin in 
plasma was 17.2 ± 0.36 µg/ml, which rapidly declined to 
6.39 ± 0.16  µg/ml  at  10  min.  The  drug  level  above  the 
MIC90 in plasma, was detected for up to 10 h. Levofloxacin 
was rapidly distributed from blood to the tissue compart-
ment as evidenced by the high values of the distribution 
coefficient, α (17.3 ±  1.65 /h) and the ratio of K12/K21 (1.83 
±  0.12). The values of AUC and Vdarea were 12.7 ± 0.12 
µg.h/ml and 0.63 ±  0.01 l/kg. The high ratio of the AUC/ 
MIC (126.9 ± 1.18) obtained in this study indicated the ex-
cellent antibacterial activity of levofloxacin in calves. The 
elimination half-life, MRT and total body clearance were 
1.38 ± 0.01 h, 1.88 ± 0.01 h and 0.32 ± 0.003 l/kg/h, respec-
tively. Based on the pharmacokinetic parameters, an ap-
propriate  intravenous  dosage  regimen  for  levofloxacin 
would be 5 mg/kg repeated at 24 h intervals when pre-
scribed with paracetamol in calves.
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Introduction 
  Under field conditions, the management of bacterial in-
fections with the administration of antibacterial with an-
algesic agents is standard treatment. Fluoroquinolones are 
known to interact with non-steroidal anti-inflammatory 
drugs at pharmacokinetic levels [20]. Fluoroquinolone re-
sistance relates directly to the human and veterinary usage 
and emerging bacterial resistance poses the single greatest 
threat to the future survival of the fluoroquinolone drugs as 
a therapeutically useful antibiotic class [8]. Levofloxacin 
[(-) -9-Fluoro-3-methyl-10-(4-methyl-1-piprazinyl)-7-oxo-2, 
3-dihydro-7 H-pyrido [1, 2, 3-de] [1, 4]-benzoxazine- 
6-carboxylic acid], a recently introduced second-gen-
eration fluoroquinolone, possesses excellent activity 
against gram-positive, gram-negative and anaerobic bac-
teria [10,22]. As compared to other fluoroquinolones, such 
as ofloxacin and ciprofloxacin, it also has more pro-
nounced bactericidal activity against organisms such as 
Pseudomonas, Enterobacteriaceae and Klebsiella [19]. 
The drug distributes well to the target body tissues and flu-
ids in the respiratory tract, skin, urine and prostate, and its 
uptake by cells makes it suitable for use against intra-
cellular pathogens [20]. Levofloxacin is metabolized in the 
liver to demethyl-levofloxacin and levofloxacin-N-oxide 
and excreted in the urine [20]. The disposition of levo-
floxacin has been investigated in man [9], rabbits [11], rats 
[17], guinea pigs [14] and crossbred calves [12,13]. 
However, there is no information on the disposition of lev-
ofloxacin on concurrent administration with paracetamol 
in cattle. In view of the alterations in the kinetic behavior of 
simultaneously administered drugs, the present study was 
undertaken to determine the disposition and appropriate 
dosage of levofloxacin following a single intravenous in-
jection when co-administered along with paracetamol in 
crossbred calves. 
Materials and Methods
  Six healthy male crossbred calves (Holstein Friesian ×  
Sahiwal), ranging between 1-1.5 years of age with an aver-
age body weight of 87.8 ± 13.1 kg were used for this study. 
The animals were maintained in the departmental animal 
shed on seasonal green fodder and water ad libitum and 
were determined to be healthy by regular clinical exa-
mination. The experimental protocol followed the ethical 
guidelines on the proper care and use of animals. The aver-
age day temperature in the shed was about 25ºC during the 358    Vinod K. Dumka 
Fig. 1. Semilogarithmic plot of the plasma concentration-time 
profile of levofloxacin following a single intravenous injection 
of 4 mg/kg body weight subsequent to a single intramuscular in-
jection of paracetamol (50 mg/kg) in crossbred calves. Values are
presented as mean ± SE of six animals. The data was analyzed ac-
cording to the two-compartment open model. Distribution (α) 
and elimination (β) phases are represented by least square re-
gression lines. The calculated points (o) of the distribution phases 
were obtained by the feathering technique.
experimental period. Levofloxacin (Hoechst Marion 
Roussel, India) was administered at a dose of 4 mg/kg body 
weight into the left jugular vein, immediately after intra-
muscular injection of paracetamol (Sarabhai Zydus 
Animal Health, India) at a dose of 50 mg/kg into the neck 
region. 
  Blood samples (5 ml) were withdrawn from the con-
tralateral jugular vein into heparinized glass centrifuge 
tubes before and at 1, 2.5, 5, 7.5, 10, 15, 20, 30 min and 1, 
1.5, 2, 2.5, 3, 4, 6, 8, 10, 16 and 24 h after administration of 
the levofloxacin. Plasma was separated by centrifugation 
at 2,000 × g for 15 min at room temperature, and kept at 
򰠏20ºC until analysis, which was usually done on the day of 
collection. 
  The concentration of levofloxacin in the plasma samples 
was estimated by a standard microbiological assay techni-
que [6] using Escherichia (E.) coli (ATCC 10536) as the 
test organism. This method estimated the level of drug hav-
ing antibacterial activity, without differentiating between 
the parent drug and its active metabolites. The assay could 
detect a minimum of 0.1 µg/ml of levofloxacin. The diame-
ter of the zone of inhibition of reference as well as study 
samples was measured with a Fisher Lilly Antibiotic Zone 
Reader (Fisher Scientific, USA). For each sample, nine 
replicates were analyzed and correlated with the zone of in-
hibition of the standard reference solution. The concen-
tration of the drug in the samples was calculated as µg/ml 
of plasma. 
  The plasma concentration-time profile of levofloxacin af-
ter its concomitant administration with paracetamol in 
each animal was used to establish various disposition ki-
netic determinants and the mean kinetic variables were ob-
tained by averaging the variables calculated for individual 
animals. Disposition kinetic parameters were calculated 
manually by the computed least-squares linear regression 
technique [15]. 
Results
  The mean plasma concentrations of levofloxacin, follow-
ing its single intravenous administration (4 mg/kg body 
weight) subsequent to a single intramuscular injection of 
paracetamol (50 mg/kg body weight), as a function of time 
on a semilogarithmic scale are presented in Fig. 1. At 1 
min, the mean plasma drug concentration was 17.2 ± 0.36 
µg/ml. The drug was detected in plasma for up to 10 h after 
dosing (0.16 ± 0.01 µg/ml). Evaluation of the results re-
vealed that the disposition pattern of levofloxacin best fit a 
2-compartment open model. It was adequately described 
by the bi-exponential equation: Cp = Ae
-αt + Be
-βt, where, Cp 
was the plasma level of levofloxacin at time t and e repre-
sents the base of the natural logarithm; A and B are the ex-
trapolated zero-time intercepts of the distribution and 
elimination phases, respectively, and α and β are the dis-
tribution and elimination rate constants, respectively. The 
disposition kinetic parameters that describe the dis-
tribution and elimination pattern of levofloxacin on co-ad-
ministration with paracetamol in the calves were calcu-
lated and are presented in Table 1. The absolute dose of lev-
ofloxacin per day was calculated using AUIC and ClB val-
ues from Table 1 according to the method of McKellar et 
al. [21]. Where, AUIC is the ratio of AUC/MIC.
Discussion
  Consistent with our findings that the disposition curve of 
levofloxacin administered alone in the calves [13] and an-
other fluoroquinolone, danofloxacin, in goats after  intra-
venous administration was  reported to follow a two-com-
partment open model [7]. An average plasma concen-
tration of 0.032-0.5 µg/ml has been reported to be the mini-
mum therapeutic concentration (MIC90) of levofloxacin Disposition of levofloxacin with paracetamol in calves    359
Table 1. Disposition parameters of levofloxacin in cross bred 
calves (n = 6) following its single intravenous administration of
4 mg/kg body weight subsequently with a single intramuscular 
injection of paracetamol (50 mg/kg)
Parameter   Unit Mean ± SE
Cp
0
A
B
α
β
t1/2α
t1/2β
K12/K21
AUC
AUMC
Vdarea
ClB
Kel
MRT
P/C
AUC/MIC
td
µg/ml
µg/ml
µg/ml
/h
/h
h
h
ratio
µg.h/ml
µg.h
2/ml
l/kg
l/kg/h
/h
h
ratio
ratio
h
19.1 ± 0.83
13.2 ± 0.80
5.97 ± 0.06
17.3 ± 1.65
0.501 ± 0.003
0.04 ± 0.01
1.38 ± 0.01
1.83 ± 0.12
12.7 ± 0.12
23.8 ± 0.29
0.63 ± 0.01
 0.32 ± 0.003
1.51 ± 0.07
1.88 ± 0.01
2.01 ± 0.12
       26.9 ± 1.18
7.35 ± 0.05
Cp
0=plasma drug concentration at time zero after intravenous dose; 
α and A=distribution rate constant from central to peripheral com-
partment and the zero time intercept of distribution phase, re-
spectively; B and β=zero time intercept of the elimination phase and
elimination rate constant, respectively; t1/2α=distribution half life; t1/2
β=elimination half life; K12 and K21 are rate constants of drug transfer
from central to peripheral and from peripheral to central compart-
ment, respectively; AUC=area under the plasma-concentration time
curve; AUMC=area under the first moment of plasma-concentration
time curve; Vd(area)=apparent volume of distribution; ClB=total body 
clearance of drug; Kel=rate constant for elimination of drug from 
central compartment; MRT=mean residence time; P/C=ratio of drug
present in peripheral to central compartment; MIC=minimum in-
hibitory concentration of levofloxacin; td=total duration of pharma-
cological effect. 
against most gram-positive, gram negative and atypical 
bacteria [9] including statphylococci, citrobactor, enter-
obactor,  E.coli, klebsiella, morgenella, proteus, hemo-
phillus, ligionella, morexella, clostridium, chlamydia and 
mycoplasma [20]. Keeping in mind the synergistic effect 
of the body immune system, and other in vivo factors, to 
cover most of the susceptible organisms, in this discussion, 
a MIC90 of 0.1 µg/ml of levofloxacin was taken into 
consideration. 
  At 1 min after injection, the plasma level (17.2 ± 0.36 µg/ 
ml) was approximately 172 fold higher than the MIC of 
levofloxacin and the drug was detected above the mini-
mum therapeutic plasma level up to 10 h after admi-
nistration. Levofloxacin was rapidly transferred from the 
central to the peripheral compartment in calves, as is evi-
dent from the low value of the distribution half-life (0.04 ±  
0.01 h) and the high ratio of K12/K21 (1.83 ± 0.12). Similar 
low values for the distribution half-life (0.06 h) were re-
ported after intravenous administration of levofloxacin 
alone in calves [13]. However, in contrast to our findings, 
a long t1/2α of 19 h was reported after intravenous admin-
istration of enrofloxacin in calves [1]. The high value of the 
P/C ratio (2.01 ± 0.12) and the apparent volume of dis-
tribution confirmed the extensive penetration of levo-
floxacin into various body fluids and tissues. The value of 
Vdarea established in the present study (0.63 ± 0.01 l/kg) 
was lower than the findings of Dumka and Srivastava [13] 
and Langtry and Lamb [20] who reported that the volume 
of distribution of levofloxacin, when administered alone 
by single intravenous injection, to be 0.74 l/kg in calves 
and 0.94 l/kg in man. However, the volume of distribution 
of other fluoroquinolones used in veterinary medicine, af-
ter intravenous administration, varied from 0.4 l/kg for en-
rofloxacin in calves [1] to 1.42 l/kg and 3.44 l/kg for dano-
floxacin in goats [7] and calves [5], respectively. The high 
value of AUC (12.7 ± 0.12 µg.h/ml) in the present study, 
which was higher than the AUC (7.66 µg.h/ml) of levo-
floxacin when administered alone in calves [12], reflected 
coverage of a vast body area by the drug concentration. 
High values of AUC of levofloxacin have been reported in 
rabbits (29.7 ± 6.3 µg.h/ml) and man (55.3 µg.h/ml) [11, 
20]. Furthermore, high values of AUC have also been re-
ported after intravenous administration of enrofloxacin in 
calves (17.8 µg.h/ml) and cows (7.42 µg.h/ml) [1,18] and 
danofloxacin (29.6 µg.h/ml) in goats [7]. The high value of 
AUC/MIC90 (126.9 ± 1.18) obtained in the present study, 
shows the excellent antibacterial activity of levofloxacin in 
calves. This ratio was higher than the values of the 
AUC/MIC ratio reported for levofloxacin (76.6) ad-
ministered intramuscularly without paracetamol in calves 
[12] and for another fluoroquinolone, danofloxacin (60.5) 
after intravenous administration in sheep [4]. The total 
body clearance of levofloxacin in the present study was 
0.32 ± 0.003 l/kg/h. This finding is in agreement with the 
ClB of 0.21 l/kg/h and 0.32 l/kg/h after a single intra-
muscular [12] and intravenous [13] administration of levo-
floxacin without paracetamol and 0.28 l/kg/h reported for 
enrofloxacin after intravenous administration in calves [1]. 
The elimination half-life of levofloxacin in calves calcu-
lated in this study (1.38 ± 0.01 h) was comparable to the t1/2β 
of 1.61 h for levofloxacin administered alone intra-
venously in calves [13], 2.3 h for norfloxacin in cattle [16] 
and 1.68 h for enrofloxacin in cows [18]. However, the 
elimination half-life of levofloxacin in the present study 
was shorter than t1/2β of 3.67 h reported for levofloxacin ad-
ministered intramuscularly without paracetamol in calves. 
[12] It was 4.67 h and 4.01 h for danofloxain in goats [2,7], 360    Vinod K. Dumka 
5.37 h in camels [3] and 6.26 h in calves [5] but longer than 
the t1/2β of 0.95 h for enrofloxacin in calves [1] after intra-
venous administration.
  The main aim of this disposition kinetic study was to de-
termine the appropriate intravenous dose regimen for 
levofloxacin. Based on the results of the present study, the 
absolute dose of levofloxacin per day, with simultaneous 
administration of paracetamol, was calculated to be 4.9 
mg/kg under field conditions. This is for most bacteria sen-
sitive to levofloxacin (several species of staphylococci, 
streptococci, including Streptococcus pneumoniae, most 
enterococci, enterobacteriaceae, E. coli, klebsiella, pro-
teus, pseudomonas, bacteroides, clostridium, haemophi-
lus, moraxella, legionella, mycoplasma and chlamydia 
[20]). The most appropriate dose regimen for levofloxacin, 
would be 5 mg/kg repeated at 24 h intervals when pre-
scribed along with paracetamol in calves. This dose was 
different from the intravenous dose of 3 mg/kg at 12 h in-
tervals [13] and the intramuscular dose of 1.5 mg/kg at 8 h 
intervals [12] reported for levofloxacin when prescribed 
alone in calves.
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